With an antisense-oligonucleotide targeting clusterin having progressed to Phase 3 clinical trials for prostate cancer, our data demonstrating that clusterin negatively affects OPCs and myelin production offers a new therapeutic avenue to potentially improve myelin integrity and memory deficits plaguing AD patients[67, 68]. Here, CLU is linked to prostate cancer.